.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

INVANZ Drug Profile

« Back to Dashboard
Invanz is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in forty-seven countries.

The generic ingredient in INVANZ is ertapenem sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ertapenem sodium profile page.

Summary for Tradename: INVANZ

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: INVANZ

Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
INVANZ
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001RXYes5,478,820*PED► subscribeY► subscribe
Merck Sharp Dohme
INVANZ
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001RXYes5,952,323*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
INVANZ
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 20015,478,820*PED► subscribe
Merck Sharp Dohme
INVANZ
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 20017,342,005*PED► subscribe
Merck Sharp Dohme
INVANZ
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 20015,652,233*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INVANZ

Drugname Dosage Strength RLD Submissiondate
ertapenemInjection1 g/vialInvanz6/20/2013

Non-Orange Book Patents for Tradename: INVANZ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,652,233 Antibiotic compounds► subscribe
7,041,836Antibiotic compounds► subscribe
6,521,612 Antibiotic compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INVANZ

Country Document Number Estimated Expiration
Germany69725696► subscribe
Russian Federation2117659► subscribe
Singapore48817► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INVANZ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0041France► subscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
2004008Lithuania► subscribePRODUCT NAME: ERTAPENEMUM ([4R,5S,6S]-3-[(3S,5S)-5-[(3-KARBOKSIFENIL) AMINO]KARBONIL]-3-PIROLIDINIL]TIO]-6-[(1R)-1HIDROKSIETIL]-4-METIL-7-OKSO-1-AZABICIKLO-[3.2.0]HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328
C027/2002Ireland► subscribeSPC027/2002: 20040929, EXPIRES: 20170417
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc